Latest filing published 16 Oct 2013 for Enanta Pharmaceuticals INC, €31.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +100.4%Entry US$19.96 · Close at T+365 US$39.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Saints Capital Granite, L.P.: trading record in brief
Saints Capital Granite, L.P. discloses dealings in Enanta Pharmaceuticals Inc to SEC (Form 4). The record holds 36 filings, for trades running from 26 March 2013 to 14 October 2013.
On the open market, the record shows 1 purchase worth €724k and 32 sales worth €4.7M. Taken together, the sales exceed the purchases by €4.0M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
The record was last updated on 16 October 2013 with an open-market sale (€31) in Enanta Pharmaceuticals Inc. The most recent open-market purchase was published on 28 March 2013, 4,974 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Saints Capital Granite, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2 shares@ US$21.05Common StockSEC:0001181431-13-054098:0
- 16 shares@ US$21.05Common StockSEC:0001181431-13-054098:1
- 22 shares@ US$21.05Common StockSEC:0001181431-13-054098:2
- 158 shares@ US$21.05Common StockSEC:0001181431-13-054098:3
- 303 shares@ US$19.8287Common StockSEC:0001181431-13-054098:4
- 2,607 shares@ US$19.8287Common StockSEC:0001181431-13-054098:5
- 3,640 shares@ US$19.8287Common StockSEC:0001181431-13-054098:6
- 25,553 shares@ US$19.8287Common StockSEC:0001181431-13-054098:7
- 236 shares@ US$22.00Common StockSEC:0001181431-13-053692:0
- 2,030 shares@ US$22.00Common StockSEC:0001181431-13-053692:1
- 2,835 shares@ US$22.00Common StockSEC:0001181431-13-053692:2
- 19,899 shares@ US$22.00Common StockSEC:0001181431-13-053692:3
- 106 shares@ US$21.0563Common StockSEC:0001181431-13-053692:4
- 910 shares@ US$21.0563Common StockSEC:0001181431-13-053692:5
- 1,271 shares@ US$21.0563Common StockSEC:0001181431-13-053692:6
- 8,920 shares@ US$21.0563Common StockSEC:0001181431-13-053692:7
- 77 shares@ US$23.6581Common StockSEC:0001181431-13-052691:0
- 39 shares@ US$22.846Common StockSEC:0001181431-13-052691:1
- 666 shares@ US$23.6581Common StockSEC:0001181431-13-052691:2
- 333 shares@ US$22.846Common StockSEC:0001181431-13-052691:3
- 930 shares@ US$23.6581Common StockSEC:0001181431-13-052691:4
- 465 shares@ US$22.846Common StockSEC:0001181431-13-052691:5
- 6,527 shares@ US$23.6581Common StockSEC:0001181431-13-052691:6
- 3,263 shares@ US$22.846Common StockSEC:0001181431-13-052691:7
- 135 shares@ US$23.1298Common StockSEC:0001144204-13-053716:0
25 of 36 declarations